{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T03:30:41Z","timestamp":1788838241116,"version":"build-2803163510"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","award":["lPI043760"],"award-info":[{"award-number":["lPI043760"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004374","name":"Medtronic","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004374","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002809","name":"Generalitat de Catalunya","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006259","name":"Teva Pharmaceutical Industries","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006259","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005774","name":"Universitat de Barcelona","doi-asserted-by":"publisher","award":["MDM-2017-0729"],"award-info":[{"award-number":["MDM-2017-0729"]}],"id":[{"id":"10.13039\/501100005774","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011110","name":"UCB","doi-asserted-by":"publisher","award":["SLT008\/18\/00191"],"award-info":[{"award-number":["SLT008\/18\/00191"]}],"id":[{"id":"10.13039\/100011110","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010566","name":"Consejer\u00eda de Salud y Familias, Junta de Andaluc\u00eda","doi-asserted-by":"publisher","award":["CIBERDEM PIE14\/00061"],"award-info":[{"award-number":["CIBERDEM PIE14\/00061"]}],"id":[{"id":"10.13039\/501100010566","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010566","name":"Consejer\u00eda de Salud y Familias, Junta de Andaluc\u00eda","doi-asserted-by":"publisher","award":["PI17\/00096"],"award-info":[{"award-number":["PI17\/00096"]}],"id":[{"id":"10.13039\/501100010566","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010566","name":"Consejer\u00eda de Salud y Familias, Junta de Andaluc\u00eda","doi-asserted-by":"publisher","award":["PI17\/00447"],"award-info":[{"award-number":["PI17\/00447"]}],"id":[{"id":"10.13039\/501100010566","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014440","name":"Ministerio de Ciencia, Innovaci\u00f3n y Universidades","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013116","name":"Merz Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013116","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","prd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Parkinsonism & Related Disorders"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.parkreldis.2020.08.018","type":"journal-article","created":{"date-parts":[[2020,8,25]],"date-time":"2020-08-25T12:16:00Z","timestamp":1598357760000},"page":"91-96","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"special_numbering":"C","title":["Peripheral insulin and amylin levels in Parkinson's disease"],"prefix":"10.1016","volume":"79","author":[{"given":"Almudena","family":"S\u00e1nchez-G\u00f3mez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gema","family":"Alcarraz-Viz\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manel","family":"Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rub\u00e9n","family":"Fern\u00e1ndez-Santiago","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Ezquerra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"C\u00e1mara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00f2nica","family":"Serrano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Novials","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esteban","family":"Mu\u00f1oz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesc","family":"Valldeoriola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaroslau","family":"Compta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Jos\u00e9","family":"Mart\u00ed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.parkreldis.2020.08.018_bib1","doi-asserted-by":"crossref","first-page":"e139","DOI":"10.1212\/WNL.0000000000005771","article-title":"Association between diabetes and subsequent Parkinson disease: a record-linkage cohort study","volume":"91","author":"De Pablo-Fernandez","year":"2018","journal-title":"Neurology"},{"issue":"11","key":"10.1016\/j.parkreldis.2020.08.018_bib2","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0142582","article-title":"Blood biomarkers associated with cognitive decline in early stage and drug-naive Parkinson's disease patients","volume":"10","author":"Santiago","year":"2015","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.parkreldis.2020.08.018_bib3","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1002\/mds.27492","article-title":"Baseline predictors for progression 4 years after Parkinson's disease diagnosis in the de novo Parkinson cohort (DeNoPa)","volume":"34","author":"Mollenhauer","year":"2019","journal-title":"Mov. Disord."},{"issue":"1\u20132","key":"10.1016\/j.parkreldis.2020.08.018_bib4","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jns.2011.12.008","article-title":"Dementia is associated with insulin resistance in patients with Parkinson's disease","volume":"315","author":"Bosco","year":"2012","journal-title":"J. Neurol. Sci."},{"issue":"12","key":"10.1016\/j.parkreldis.2020.08.018_bib5","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1016\/j.parkreldis.2014.10.008","article-title":"Diabetes mellitus is independently associated with more severe cognitive impairment in Parkinson disease","volume":"20","author":"Bohnen","year":"2014","journal-title":"Park. Relat. Disord."},{"issue":"6","key":"10.1016\/j.parkreldis.2020.08.018_bib6","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.parkreldis.2014.02.016","article-title":"Diabetes is associated with postural and cognitive domains in Parkinson's disease. Results from a single-center study","volume":"20","author":"Giuntini","year":"2014","journal-title":"Park. Relat. Disord."},{"issue":"5","key":"10.1016\/j.parkreldis.2020.08.018_bib7","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.parkreldis.2013.01.016","article-title":"Diabetes is associated with postural instability and gait difficulty in Parkinson disease","volume":"19","author":"Kotagal","year":"2013","journal-title":"Park. Relat. Disord."},{"issue":"Pt 2","key":"10.1016\/j.parkreldis.2020.08.018_bib8","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1093\/brain\/aws009","article-title":"Parkinson's disease, insulin resistance and novel agents of neuroprotection","volume":"136","author":"Aviles-Olmos","year":"2013","journal-title":"Brain"},{"issue":"3","key":"10.1016\/j.parkreldis.2020.08.018_bib9","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/nrneurol.2017.185","article-title":"Brain insulin resistance in type 2 diabetes and Alzheimer disease: concepts and conundrums","volume":"14","author":"Arnold","year":"2018","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.parkreldis.2020.08.018_bib10","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.pneurobio.2016.10.001","article-title":"Insulin resistance and Parkinson's disease: a new target for disease modification?","volume":"145\u2013146","author":"Athauda","year":"2016","journal-title":"Prog. Neurobiol."},{"issue":"6645","key":"10.1016\/j.parkreldis.2020.08.018_bib11","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/42166","article-title":"Alpha-synuclein in Lewy bodies","volume":"388","author":"Spillantini","year":"1997","journal-title":"Nature"},{"issue":"44","key":"10.1016\/j.parkreldis.2020.08.018_bib12","doi-asserted-by":"crossref","first-page":"12473","DOI":"10.1073\/pnas.1610371113","article-title":"Cross-talk between amyloidogenic proteins in type-2 diabetes and Parkinson's disease","volume":"113","author":"Horvath","year":"2016","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"3","key":"10.1016\/j.parkreldis.2020.08.018_bib13","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1210\/er.2007-0037","article-title":"Islet amyloid in type 2 diabetes,and the toxic oligomer hypothesis","volume":"29","author":"Haataja","year":"2008","journal-title":"Endocr. Rev."},{"issue":"7","key":"10.1016\/j.parkreldis.2020.08.018_bib14","doi-asserted-by":"crossref","first-page":"2970","DOI":"10.1096\/fj.15-270553","article-title":"Islet amyloid polypeptide exerts a novel autocrine action in \u03b2-cell signaling and proliferation","volume":"29","author":"Visa","year":"2015","journal-title":"Faseb. J."},{"issue":"10","key":"10.1016\/j.parkreldis.2020.08.018_bib15","doi-asserted-by":"crossref","first-page":"928","DOI":"10.2174\/1567205011666141107124538","article-title":"Islet amyloid polypeptide (IAPP): a second amyloid in Alzheimer's disease","volume":"11","author":"Fawver","year":"2014","journal-title":"Curr. Alzheimer Res."},{"issue":"2","key":"10.1016\/j.parkreldis.2020.08.018_bib16","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/mp.2014.17","article-title":"Intraperitoneal injection of the pancreatic peptide amylin potently reduces behavioral impairment and brain amyloid pathology in murine models of Alzheimer's disease","volume":"20","author":"Zhu","year":"2015","journal-title":"Mol. Psychiatr."},{"issue":"4","key":"10.1016\/j.parkreldis.2020.08.018_bib17","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1002\/ana.25570","article-title":"Amylin as a potential link between type 2 diabetes and alzheimer disease","volume":"86","author":"Martinez-Valbuena","year":"2019","journal-title":"Ann. Neurol."},{"issue":"8","key":"10.1016\/j.parkreldis.2020.08.018_bib18","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.9826","article-title":"Association of plasma amylin concentration with alzheimer disease and brain structure in older adults","volume":"2","author":"Zhu","year":"2019","journal-title":"JAMA Netw Open"},{"issue":"6","key":"10.1016\/j.parkreldis.2020.08.018_bib19","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0218561","article-title":"Levels of islet amyloid polypeptide in cerebrospinal fluid and plasma from patients with Alzheimer's disease","volume":"14","author":"Schultz","year":"2019","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.parkreldis.2020.08.018_bib20","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1007\/s00401-018-1832-0","article-title":"Interaction of amyloidogenic proteins in pancreatic \u03b2 cells from subjects with synucleinopathies","volume":"135","author":"Martinez-Valbuena","year":"2018","journal-title":"Acta Neuropathol."},{"issue":"12","key":"10.1016\/j.parkreldis.2020.08.018_bib21","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1002\/mds.26424","article-title":"MDS clinical diagnostic criteria for Parkinson's disease","volume":"30","author":"Postuma","year":"2015","journal-title":"Mov. Disord."},{"issue":"12","key":"10.1016\/j.parkreldis.2020.08.018_bib22","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1111\/jgs.12035","article-title":"Diabetes in older adults: a consensus report","volume":"60","author":"Kirkman","year":"2012","journal-title":"J. Am. Geriatr. Soc."},{"issue":"15","key":"10.1016\/j.parkreldis.2020.08.018_bib23","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1002\/mds.23429","article-title":"Systematic review of levodopa dose equivalency reporting in Parkinson's disease","volume":"25","author":"Tomlinson","year":"2010","journal-title":"Mov. Disord."},{"key":"10.1016\/j.parkreldis.2020.08.018_bib24","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.parkreldis.2018.05.026","article-title":"Glucose dysregulation in Parkinson's disease: too much glucose or not enough insulin?","volume":"55","author":"Marques","year":"2018","journal-title":"Park. Relat. Disord."},{"issue":"7","key":"10.1016\/j.parkreldis.2020.08.018_bib25","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.arcmed.2019.10.013","article-title":"Islet function changes among the elderly population","volume":"50","author":"Sui","year":"2019","journal-title":"Arch. Med. Res."},{"issue":"2","key":"10.1016\/j.parkreldis.2020.08.018_bib26","doi-asserted-by":"crossref","first-page":"259","DOI":"10.3233\/JPD-181305","article-title":"High prevalence of undiagnosed insulin resistance in non-diabetic subjects with Parkinson's disease","volume":"8","author":"Hogg","year":"2018","journal-title":"J. Parkinsons Dis."},{"issue":"5","key":"10.1016\/j.parkreldis.2020.08.018_bib27","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0126804","article-title":"The brain response to peripheral insulin declines with age: a contribution of the blood-brain barrier?","volume":"10","author":"Sartorius","year":"2015","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.parkreldis.2020.08.018_bib28","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.bbrc.2015.09.002","article-title":"Insulin-degrading enzyme is activated by the C-terminus of \u03b1-synuclein","volume":"466","author":"Sharma","year":"2015","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.parkreldis.2020.08.018_bib29","doi-asserted-by":"crossref","first-page":"12531","DOI":"10.1038\/srep12531","article-title":"Insulin-degrading enzyme prevents \u03b1-synuclein fibril formation in a nonproteolytical manner","volume":"5","author":"Sharma","year":"2015","journal-title":"Sci. Rep."},{"issue":"2","key":"10.1016\/j.parkreldis.2020.08.018_bib30","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/BF00500385","article-title":"Plasma islet amyloid polypeptide (Amylin) levels and their responses to oral glucose in type 2 (non-insulin-dependent) diabetic patients","volume":"34","author":"Sanke","year":"1991","journal-title":"Diabetologia"},{"issue":"1","key":"10.1016\/j.parkreldis.2020.08.018_bib31","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/0047-6374(95)01664-3","article-title":"Age-related changes in amylin secretion","volume":"86","author":"Edwards","year":"1996","journal-title":"Mech. Ageing Dev."},{"issue":"5","key":"10.1016\/j.parkreldis.2020.08.018_bib32","first-page":"E785","article-title":"Human aging is associated with parallel reductions in insulin and amylin release","volume":"275","author":"Dechenes","year":"1998","journal-title":"Am. J. Physiol."},{"key":"10.1016\/j.parkreldis.2020.08.018_bib33","doi-asserted-by":"crossref","first-page":"216","DOI":"10.3389\/fnins.2015.00216","article-title":"Amylin at the interface between metabolic and neurodegenerative disorders","volume":"9","author":"Lutz","year":"2015","journal-title":"Front. Neurosci."},{"issue":"11","key":"10.1016\/j.parkreldis.2020.08.018_bib34","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1002\/mds.22173","article-title":"Cut-off score of the Mattis dementia rating scale for screening dementia in Parkinson's disease","volume":"23","author":"Llebaria","year":"2008","journal-title":"Mov. Disord."},{"issue":"10103","key":"10.1016\/j.parkreldis.2020.08.018_bib35","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1016\/S0140-6736(17)31585-4","article-title":"Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial","volume":"390","author":"Athauda","year":"2017","journal-title":"Lancet"}],"container-title":["Parkinsonism & Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802020306842?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802020306842?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T08:48:22Z","timestamp":1774860502000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1353802020306842"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":35,"alternative-id":["S1353802020306842"],"URL":"https:\/\/doi.org\/10.1016\/j.parkreldis.2020.08.018","relation":{},"ISSN":["1353-8020"],"issn-type":[{"value":"1353-8020","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Peripheral insulin and amylin levels in Parkinson's disease","name":"articletitle","label":"Article Title"},{"value":"Parkinsonism & Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.parkreldis.2020.08.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}